CYP26B1 CRISPR/Cas9 KO Plasmid (h): sc-403610
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYP26B1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CYP26B1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CYP26B1 Antibody (2G7): sc-293493
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP26B1 CRISPR/Cas9 KO Plasmid (h) | sc-403610 | 20 µg | $397.00 |
Overview
CYP26B1 encodes a cytochrome P450 retinoic acid hydroxylase that catalyzes oxidative catabolism of all-trans-retinoic acid and related retinoids, thereby controlling intracellular retinoid gradients. By tuning retinoic acid availability, CYP26B1 influences RA receptor (RAR/RXR)-dependent transcriptional programs that regulate differentiation, morphogenesis, and tissue homeostasis. Its activity intersects with developmental signaling networks and cellular fate decisions through retinoid metabolism and downstream gene regulatory pathways. Dysregulated CYP26B1 expression or function has been implicated in congenital developmental phenotypes and in altered retinoid signaling contexts relevant to cancer biology and inflammatory processes, making it a useful node for mechanistic studies of retinoid homeostasis.
CYP26B1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CYP26B1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CYP26B1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CYP26B1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CYP26B1 protein expression.
This CRISPR knockout system enables efficient generation of CYP26B1-deficient cell models for investigation of CYP26B1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CYP26B1 exon(s) critical for CYP26B1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CYP26B1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CYP26B1 CRISPR/Cas9 KO Plasmid (h) and CYP26B1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CYP26B1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CYP26B1 HDR Plasmid (h) and CYP26B1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CYP26B1 homology arms to support homology-directed repair at defined CYP26B1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.